After 340B Hearing and New Bills Emerging; The Likely Path Forward
By Ted Slafsky
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight. In fact, until the June 4th House Energy & Commerce (E&C) Oversight and Investigations Subcommittee hearing, there had not been a hearing specifically devoted to the 340B program since March 2018.
This is due to the fact that most in Congress would prefer to avoid issues that have two powerful interest groups with often diametrically opposite opinions on key matters. What has been the general approach of Congress when they are called upon to address the tricky, often contentious issues facing 340B stakeholders? Let the Health Resources and Services Administration deal with it, or if need be, the federal courts. Read More >
